Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 1.00 |
| ▸ | MAOB | P27338 | 10/20 | 0.76 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | HTR1B | P28222 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.60 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580482 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL14880424 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL14880741 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL20580481 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL16394605 | 0.86 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL14880593 | 0.86 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL16394444 | 0.86 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL16394111 | 0.86 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL21840994 | 0.86 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 | |
| SCHEMBL16394112 | 0.86 | KDM1A (1.00) | KDM1AMAOAMAOBCISD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107266345-B | (hetero) arylcyclopropylamine compounds as LSD1 inhibitors | 奥瑞泽恩基因组学股份有限公司 | 2021-08-17 | — | — | CN | claimed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | claimed |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2017-01-12 | — | — | US | claimed |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-01-22 | — | — | US | claimed |
| EP-2768805-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2014-08-27 | — | — | EP | claimed |
| WO-2013057320-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | claimed |
| EP-3941465-B1 | METHODS OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER USING KDM1A INHIBITORS SUCH AS THE COMPOUND VAFIDEMSTAT | ORYZON GENOMICS SA (ES) | 2025-09-17 | — | — | EP | disclosed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| EP-4512473-A2 | METHODS OF TREATING BEHAVIOR ALTERATIONS | Oryzon Genomics, S.A. (ES) | 2025-02-26 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| US-20240277673-A1 | METHODS OF TREATING BEHAVIOR ALTERATIONS | ORYZON GENOMICS SA (ES) | 2024-08-22 | — | — | US | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| US-20220151998-A1 | METHODS OF TREATING BORDERLINE PERSONALITY DISORDER | ORYZON GENOMICS SA (ES) | 2022-05-19 | — | — | US | disclosed |
| WO-2017013061-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS, S.A. (ES) | 2017-01-26 | — | — | WO | disclosed |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2017-01-12 | — | — | US | disclosed |
| WO-2016198649-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS, S.A. (ES) | 2016-12-15 | — | — | WO | disclosed |
| US-9487512-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-11-08 | — | — | US | disclosed |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-01-22 | — | — | US | disclosed |
| EP-2768805-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013057320-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOA 143/4885MAOB 165/4885 |
| US-20220151998-A1 | METHODS OF TREATING BORDERLINE PERSONALITY DISORDER | KDM4A, KDM4B, KDM2B | KDM1A 12/4885MAOA 184/4885MAOB 111/4885 |
| US-20240277673-A1 | METHODS OF TREATING BEHAVIOR ALTERATIONS | DOT1L, KDM1A, KDM1B | KDM1A 2/4885MAOA 512/4885MAOB 437/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOA 143/4885MAOB 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.